Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$8,933,000 | $8,040,000 | $6,345,000 | $7,014,000 |
| Dep. & Amort. | $9,600,000 | $9,760,000 | $10,276,000 | $10,686,000 |
| Deferred Tax | -$2,089,000 | -$3,288,000 | -$2,738,000 | -$1,393,000 |
| Stock-Based Comp. | $507,000 | $518,000 | $457,000 | $583,000 |
| Change in WC | $810,000 | -$1,914,000 | -$2,229,000 | -$1,253,000 |
| Other Non-Cash | $15,295,000 | $744,000 | $955,000 | $570,000 |
| Operating Cash Flow | $15,190,000 | $13,860,000 | $13,066,000 | $16,207,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,248,000 | -$1,209,000 | -$1,118,000 | -$973,000 |
| Net Acquisitions | -$21,821,000 | -$260,000 | -$2,981,000 | -$862,000 |
| Inv. Purchases | -$769,000 | -$1,774,000 | -$3,592,000 | -$5,478,000 |
| Inv. Sales/Matur. | $1,387,000 | $948,000 | $6,629,000 | $6,775,000 |
| Other Inv. Act. | $1,099,000 | $0 | $0 | $0 |
| Investing Cash Flow | -$21,352,000 | -$2,295,000 | -$1,062,000 | -$538,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $10,096,000 | $456,000 | -$5,311,000 | -$6,182,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | -$5,155,000 | -$8,001,000 | -$6,287,000 |
| Dividends Paid | -$4,863,000 | -$4,744,000 | -$4,634,000 | -$4,396,000 |
| Other Fin. Act. | -$106,000 | $27,000 | $984,000 | $641,000 |
| Financing Cash Flow | $5,127,000 | -$9,416,000 | -$16,962,000 | -$16,224,000 |
| Forex Effect | -$137,000 | $45,000 | -$33,000 | -$102,000 |
| Net Chg. in Cash | -$1,172,000 | $2,194,000 | -$4,991,000 | -$657,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $11,519,000 | $9,325,000 | $14,316,000 | $14,973,000 |
| End Cash | $10,347,000 | $11,519,000 | $9,325,000 | $14,316,000 |
| Free Cash Flow | $13,942,000 | $12,651,000 | $11,948,000 | $15,234,000 |